Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Onconova Therapeutic (ONTX)

Onconova Therapeutic (ONTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,904
  • Shares Outstanding, K 21,003
  • Annual Sales, $ 230 K
  • Annual Income, $ -18,960 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.38
  • Price/Sales 91.38
  • Price/Cash Flow N/A
  • Price/Book 1.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings $-0.23 on 11/14/23
  • Next Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7655 +30.02%
on 04/02/24
1.1000 -9.52%
on 03/28/24
+0.1654 (+19.93%)
since 03/01/24
3-Month
0.6500 +53.12%
on 02/15/24
1.1000 -9.52%
on 03/28/24
+0.2053 (+25.99%)
since 01/02/24
52-Week
0.5509 +80.67%
on 10/13/23
1.4500 -31.36%
on 05/08/23
+0.2646 (+36.21%)
since 03/31/23

Most Recent Stories

More News
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Key Management Promotions

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting

NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)
Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on...

ONTX : 0.9953 (-0.47%)

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Key Turning Points

3rd Resistance Point 1.3095
2nd Resistance Point 1.1548
1st Resistance Point 1.0750
Last Price 0.9953
1st Support Level 0.8405
2nd Support Level 0.6858
3rd Support Level 0.6060

See More

52-Week High 1.4500
Fibonacci 61.8% 1.1065
Fibonacci 50% 1.0005
Last Price 0.9953
Fibonacci 38.2% 0.8944
52-Week Low 0.5509

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar